Rabbani Syed Imam, Devi Kshama, Khanam Salma
Department of Pharmacology, Al-Ameen College of Pharmacy, Opp. Lalbagh Main Gate, Hosur Road, Bangalore-560 027, India.
J Pharmacol Pharmacother. 2010 Jan;1(1):18-23. doi: 10.4103/0976-500X.64531.
To evaluate the protective effect of glibenclamide against the experimental diabetes-induced nuclear damage in Wistar rats.
The anti-mutagenic effect of glibenclamide (0.5, 5 and 50 mg/kg, p.o daily for 4 weeks) was evaluated against the nicotinamide (NA)-streptozotocin (STZ) induced type-2 diabetes mellitus using bone marrow micronucleus and sperm abnormalities tests. The antioxidant status was tested by estimating the serum levels of lipid peroxidation (LPO), catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx).
The results indicated that glibenclamide at 50 mg/kg decreased the frequency of micronuclei in erythrocytes (P < 0.05) and sperm shape abnormality (P < 0.01) besides enhancing the antioxidant status (P < 0.05) in the diabetic rats. However, glibenclamide treatment did not enhance the polychromatic and normochromatic erythrocytes (P/N) ratio and sperm count in the diabetic condition.
The observations indicate that the glibenclamide has anti-mutagenic potential which could be related to the antioxidant effect and might also possess anti-proliferative property.
评估格列本脲对实验性糖尿病诱导的Wistar大鼠核损伤的保护作用。
采用骨髓微核试验和精子畸形试验,评估格列本脲(0.5、5和50mg/kg,每日口服,持续4周)对烟酰胺(NA)-链脲佐菌素(STZ)诱导的2型糖尿病的抗诱变作用。通过测定血清脂质过氧化(LPO)、过氧化氢酶(CAT)、超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GPx)水平来检测抗氧化状态。
结果表明,50mg/kg的格列本脲可降低糖尿病大鼠红细胞微核频率(P<0.05)和精子形态异常率(P<0.01),同时增强抗氧化状态(P<0.05)。然而,格列本脲治疗并未提高糖尿病状态下的嗜多染红细胞与正常红细胞(P/N)比值和精子计数。
观察结果表明,格列本脲具有抗诱变潜力,这可能与其抗氧化作用有关,也可能具有抗增殖特性。